Belsomra (Suvorexant) Adolescent (12 to 17) Monitoring: What Clinicians Need to Know
A clinical guide to monitoring suvorexant (Belsomra) in adolescents aged 12 to 17, covering dosing, sleep-architecture effects, mental-health surveillance, growth considerations, and when to discontinue.
Read clinical review